Fibrin sealant group,n = 16 | Control group,n = 14 | ||||
---|---|---|---|---|---|
Variable | No.a | % of total | No.a | % of total | P value |
Median age, years (range) | 52 (38–91) | 60 (18–73) | 0.79 | ||
Sex, male/female | 12/4 | 75/25 | 7/7 | 50/50 | 0.16 |
Median BMI, kg/m2 (range) | 28.3 (19.6–42.1) | 32.3 (21–48.6) | 0.15 | ||
Comorbidities | |||||
Tobacco use | 1 | 6 | 2 | 14 | 0.58 |
Diabetes | 1 | 6 | 4 | 29 | 0.16 |
AJCC tumor stage | 1.00 | ||||
III | 14 | 88 | 13 | 93 | |
IV | 2 | 12 | 1 | 7 | |
Melanoma treatment prior to ILND | |||||
Surgery | 0.34 | ||||
None/FNA | 5 | 31 | 4 | 29 | |
SLN biopsy | 6 | 38 | 8 | 57 | |
Excisional biopsy/WLE | 5 | 31 | 2 | 14 | |
Systemic therapy | 0.27 | ||||
Chemotherapy | 2 | 12 | 0 | 0.48 | |
Interferon | 1 | 6 | 2 | 14 | 0.59 |
Interleukin-2 | 1 | 6 | 0 | 1.00 |